![]() In patients with prevalent LABA or LAMA use, the risk of CVD was absent or reduced. ![]() 001) increased cardiovascular risk within 30 days of initiation, and new LAMA use was associated with a 1.52 fold (95% CI, 1.28-1.80 P less than. New LABA use was associated with a 1.50-fold (95% confidence interval, 1.35-1.67 P less than. Logistical regression was performed to estimate the odds ratios of CVD from LABA and LAMA treatment. LABA or LAMA use was measured in the year preceding the cardiovascular event and stratified by duration since initiation of LABA or LAMA treatment. During a mean follow-up of 2.0 years, 37,719 patients experienced a cardiovascular event, and 146,139 matched controls were identified. Synopsis: This study included 284,200 LABA and LAMA naive patients who were aged 40 years or older and had COPD (mean age, 71.4 years) it retrieved health care claims data from 2007 through 2011 for these patients from the Taiwan National Health Insurance Research Database. This study aims to assess the association between LABA or LAMA use in patients with COPD and the risk of CVD. The findings have been confounded by incomplete medical records, exclusion of patients with CVD in bronchodilator trials, and high patient drop out rates. Prior studies have reported a possible interaction between LABA or LAMA use and increased rates of cardiovascular events however, the results have been variable. Background: Long-acting inhaled bronchodilator use (LABA or LAMA) in patients with COPD is the mainstay of treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |